Corcept Therapeutics Incorporated, a pharmaceutical company, develops drugs for the treatment of severe psychiatric and neurological diseases. Its lead product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor. The company is in Phase 3 clinical trials for CORLUX in the United States and Europe for the treatment of the psychotic features of psychotic major depression or PMD. It also conducts a proof-of-concept study evaluating the capacity of CORLUX to mitigate weight gain associated with the use of olanzapine. The company was co-founded by Alan F. Schatzberg and Joseph K. Belanoff in 1998 and is based in Menlo Park, California.